Healthcare / Medical DevicesShanghai
$10.34
-0.17 (-1.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-63.4M · quality 44.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.9B
P/E
206.8x
↑EV/EBITDA
16.0x
↑ROE
0.9%
↑Gross Margin
64.8%
↑Debt/Equity
0.33
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-23.1%
FCF CAGR
-60.5%
FCF margin
3.5%
FCF / Net income
2.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.81B · net income $23.3M · FCF $62.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.81B | $1.81B | $2.01B | $2.05B | $3.98B |
| Net Income | $23.3M | $23.3M | $301.5M | $355.0M | $1.01B |
| EBITDA | $407.1M | $407.1M | $571.1M | $537.4M | $1.34B |
| EPS | 0.04 | 0.04 | 0.53 | 0.62 | 1.78 |
| Gross Margin | 64.8% | 64.8% | 65.3% | 56.8% | 54.0% |
| Operating Margin | 12.8% | 12.8% | 19.4% | 15.4% | 32.0% |
| Net Margin | 1.3% | 1.3% | 15.0% | 17.3% | 25.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.33 | 0.33 | 0.33 | 0.22 | 0.20 |
| Current Ratio | 2.19 | 2.19 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $62.6M | $62.6M | $-63.4M | $-735.9M | $1.02B |
| Returns | |||||
| ROE | 0.9% | 0.9% | 10.9% | 13.9% | 41.9% |
| Valuation | |||||
| P/E | 206.80 | 206.80 | 30.23 | 36.89 | 10.84 |
| EV/EBITDA | 16.02 | 16.02 | 16.73 | 24.49 | 7.61 |
| P/B | 2.24 | 2.24 | 3.31 | 5.12 | 4.54 |
| Growth & Yield | |||||
| Revenue Growth | -10.0% | -10.0% | -2.0% | -48.4% | — |
| EPS Growth | -92.5% | -92.5% | -14.5% | -65.2% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
184.1%
EPS terminal req.
$0.92
Spread vs growth
-276.6%
5Y implied EPS CAGR
94.4%
EPS terminal req.
$1.11
Spread vs growth
-186.8%
10Y implied EPS CAGR
46.2%
EPS terminal req.
$1.79
Spread vs growth
-138.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.8%
Start / end P/E
28.2x → 258.5x
EPS bridge
0.53 → 0.04
Residual
-755.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.